Preoperative extended field radiation with I-125 seed implant in prostatic cancer

a preliminary report of a randomized study

Komanduri Charyulu, Norman L Block, Anam Sudarsanam

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

This study began in 1972, when randomly allocated patients received preoperative x-ray therapy to the pelvis and para-aortic areas to a dose of 3000 rad in 14 fractions; following this treatment retropubic extraperitoneal exposure of the prostate and node dissection were performed. Iodine-125 seeds were implanted in the prostate. Patients with positive nodes received postoperative radiation therapy to tolerance doses while those with negative nodes were only observed with no further therapy. In the alternate arm, the patients underwent straight retropubic extraperitoneal exposure of the prostate, node dissection, and Iodine-125 seed implant. If the nodes were positive, the patients received en bloc pelvic and para-aortic radiation to tolerance. Patients in this arm with negative nodes again received no further therapy. The aggregate dose was 5400 rad to the pelvis and was about 4400 rad to para-aortic nodes in both arms where the nodes were found to be metastatic. Thirty-two patients were evaluable for minimum of follow-up of two years with equal numbers in each group. Eight of 17 patients who had positive nodes in both the arms and who received extended field x-ray therapy, were disease-free with median survival of 3 1 2 years. Two patients in the preoperative radiation group and six in the alternate group had local failures. The pattern of survival and dissemination, otherwise were similar as of this writing.

Original languageEnglish
Pages (from-to)1957-1961
Number of pages5
JournalInternational journal of radiation oncology, biology, physics
Volume5
Issue number11-12
DOIs
StatePublished - Jan 1 1979

Fingerprint

radiation distribution
seeds
Prostatic Neoplasms
Seeds
cancer
Radiation
therapy
Arm
iodine 125
Prostate
dissection
pelvis
Pelvis
Iodine
dosage
Dissection
X-Rays
Therapeutics
Survival
Radiation Tolerance

Keywords

  • en bloc pelvic and para-aortic radiation
  • I-125 seed implant
  • Preoperative x-ray
  • Retropubic extraperitoneal exposure

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Preoperative extended field radiation with I-125 seed implant in prostatic cancer : a preliminary report of a randomized study. / Charyulu, Komanduri; Block, Norman L; Sudarsanam, Anam.

In: International journal of radiation oncology, biology, physics, Vol. 5, No. 11-12, 01.01.1979, p. 1957-1961.

Research output: Contribution to journalArticle

@article{0db5727114874f1ab02490df39a3304c,
title = "Preoperative extended field radiation with I-125 seed implant in prostatic cancer: a preliminary report of a randomized study",
abstract = "This study began in 1972, when randomly allocated patients received preoperative x-ray therapy to the pelvis and para-aortic areas to a dose of 3000 rad in 14 fractions; following this treatment retropubic extraperitoneal exposure of the prostate and node dissection were performed. Iodine-125 seeds were implanted in the prostate. Patients with positive nodes received postoperative radiation therapy to tolerance doses while those with negative nodes were only observed with no further therapy. In the alternate arm, the patients underwent straight retropubic extraperitoneal exposure of the prostate, node dissection, and Iodine-125 seed implant. If the nodes were positive, the patients received en bloc pelvic and para-aortic radiation to tolerance. Patients in this arm with negative nodes again received no further therapy. The aggregate dose was 5400 rad to the pelvis and was about 4400 rad to para-aortic nodes in both arms where the nodes were found to be metastatic. Thirty-two patients were evaluable for minimum of follow-up of two years with equal numbers in each group. Eight of 17 patients who had positive nodes in both the arms and who received extended field x-ray therapy, were disease-free with median survival of 3 1 2 years. Two patients in the preoperative radiation group and six in the alternate group had local failures. The pattern of survival and dissemination, otherwise were similar as of this writing.",
keywords = "en bloc pelvic and para-aortic radiation, I-125 seed implant, Preoperative x-ray, Retropubic extraperitoneal exposure",
author = "Komanduri Charyulu and Block, {Norman L} and Anam Sudarsanam",
year = "1979",
month = "1",
day = "1",
doi = "10.1016/0360-3016(79)90945-3",
language = "English",
volume = "5",
pages = "1957--1961",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "11-12",

}

TY - JOUR

T1 - Preoperative extended field radiation with I-125 seed implant in prostatic cancer

T2 - a preliminary report of a randomized study

AU - Charyulu, Komanduri

AU - Block, Norman L

AU - Sudarsanam, Anam

PY - 1979/1/1

Y1 - 1979/1/1

N2 - This study began in 1972, when randomly allocated patients received preoperative x-ray therapy to the pelvis and para-aortic areas to a dose of 3000 rad in 14 fractions; following this treatment retropubic extraperitoneal exposure of the prostate and node dissection were performed. Iodine-125 seeds were implanted in the prostate. Patients with positive nodes received postoperative radiation therapy to tolerance doses while those with negative nodes were only observed with no further therapy. In the alternate arm, the patients underwent straight retropubic extraperitoneal exposure of the prostate, node dissection, and Iodine-125 seed implant. If the nodes were positive, the patients received en bloc pelvic and para-aortic radiation to tolerance. Patients in this arm with negative nodes again received no further therapy. The aggregate dose was 5400 rad to the pelvis and was about 4400 rad to para-aortic nodes in both arms where the nodes were found to be metastatic. Thirty-two patients were evaluable for minimum of follow-up of two years with equal numbers in each group. Eight of 17 patients who had positive nodes in both the arms and who received extended field x-ray therapy, were disease-free with median survival of 3 1 2 years. Two patients in the preoperative radiation group and six in the alternate group had local failures. The pattern of survival and dissemination, otherwise were similar as of this writing.

AB - This study began in 1972, when randomly allocated patients received preoperative x-ray therapy to the pelvis and para-aortic areas to a dose of 3000 rad in 14 fractions; following this treatment retropubic extraperitoneal exposure of the prostate and node dissection were performed. Iodine-125 seeds were implanted in the prostate. Patients with positive nodes received postoperative radiation therapy to tolerance doses while those with negative nodes were only observed with no further therapy. In the alternate arm, the patients underwent straight retropubic extraperitoneal exposure of the prostate, node dissection, and Iodine-125 seed implant. If the nodes were positive, the patients received en bloc pelvic and para-aortic radiation to tolerance. Patients in this arm with negative nodes again received no further therapy. The aggregate dose was 5400 rad to the pelvis and was about 4400 rad to para-aortic nodes in both arms where the nodes were found to be metastatic. Thirty-two patients were evaluable for minimum of follow-up of two years with equal numbers in each group. Eight of 17 patients who had positive nodes in both the arms and who received extended field x-ray therapy, were disease-free with median survival of 3 1 2 years. Two patients in the preoperative radiation group and six in the alternate group had local failures. The pattern of survival and dissemination, otherwise were similar as of this writing.

KW - en bloc pelvic and para-aortic radiation

KW - I-125 seed implant

KW - Preoperative x-ray

KW - Retropubic extraperitoneal exposure

UR - http://www.scopus.com/inward/record.url?scp=0018609287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018609287&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(79)90945-3

DO - 10.1016/0360-3016(79)90945-3

M3 - Article

VL - 5

SP - 1957

EP - 1961

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 11-12

ER -